Danish Electrical Stock News

If you are wondering whether ISS shares still offer value at around kr218.20, you are not alone. Many investors are asking if the current price fairly reflects the business. The stock has had a mixed run, with a 3.4% decline over the last 7 days and an 11.0% decline over the last 30 days, while the 1 year return sits at 39.2% and the 5 year return at 87.9%. Recent news around ISS has focused on its role as a large facilities services provider and how it is positioning itself with customers...

For investors wondering whether Bavarian Nordic is attractively priced at its current level or whether the recent share price leaves less room for upside, this article walks through what the numbers indicate about value. The stock last closed at kr188.25, with returns of a 4.4% decline over 7 days, a 1.7% decline over 30 days, a 2.4% decline year to date, a 12.1% gain over 1 year, a 9.6% decline over 3 years, and a 14.0% decline over 5 years. Recent headlines around Bavarian Nordic have kept...

Recent performance snapshot A.P. Møller - Mærsk (CPSE:MAERSK B) has drawn fresh investor interest after a period where the share price shows single day, week, month and past 3 months returns all in positive territory. See our latest analysis for A.P. Møller - Mærsk. That recent strength builds on wider momentum, with an 18.2% year to date share price return and a 1 year total shareholder return of 53.3%, suggesting investors are reassessing both growth prospects and risk around A.P. Møller -...

FLSmidth (CPSE:FLS) is back in focus after a cluster of board and executive changes coincided with its full year 2025 results, which showed lower sales and earnings per share compared with the previous year. See our latest analysis for FLSmidth. The recent leadership reshuffle and completion of the DKK 1,054 million buyback sit alongside a mixed price picture, with a 31.91% 90 day share price return and a 55.03% 1 year total shareholder return suggesting positive momentum after a softer past...

Novo Nordisk (CPSE:NOVO B) has entered a high-value partnership with Vivtex Corporation to develop next-generation oral biologic medicines for obesity and diabetes. The agreement focuses on turning injectable peptide therapeutics into oral treatments using Vivtex’s drug delivery platform and Novo Nordisk’s metabolic disease expertise. The collaboration aims to broaden treatment options for patients who currently rely on injectable therapies. Novo Nordisk, trading at DKK234.5 per share, has...

Carlsberg has confirmed it is considering an IPO of its India business. The company publicly acknowledged ongoing speculation around the India listing plans. The potential IPO would give investors a direct way to gain exposure to Carlsberg’s India operations. For investors watching CPSE:CARL B, the confirmation around a possible India IPO comes at a time when the shares trade at DKK969.2. The stock is up 13.6% over the past 30 days and 17.4% year to date, with a 12.3% return over 5 years...

Per Aarsleff Holding A/S reported first-quarter 2025/26 results with sales rising to DKK 6,180 million and net income reaching DKK 187 million, modestly above the prior year. Separately, PURIS announced that PAA will become a part owner in a new LiquiForce partnership, extending Per Aarsleff’s technical footprint in Canadian infrastructure rehabilitation through shared LED-light curing and lateral renewal solutions. We’ll now examine how Per Aarsleff’s higher quarterly earnings and...

TORM plc recently reported full-year 2025 results showing sales of US$1.34 billion and net income of US$285.3 million, alongside new 2026 TCE earnings guidance of US$850 million to US$1.25 billion. The board also approved a Q4 2025 interim dividend of US$0.70 per share, highlighting management’s willingness to return substantial cash to shareholders even as earnings moderated year over year. With this combination of firm 2026 TCE guidance and a sizeable Q4 dividend, we’ll now examine how the...

CEO transition puts leadership in focus for Bavarian Nordic (CPSE:BAVA) Bavarian Nordic (CPSE:BAVA) has moved into the spotlight after announcing that long-serving CEO Paul Chaplin will step down for personal reasons. The board is now beginning the search for his successor. See our latest analysis for Bavarian Nordic. Beyond the CEO news, Bavarian Nordic’s shares have been relatively steady, with a 1-year total shareholder return of 18.16% and more muted recent share price returns around the...

Scandinavian Tobacco Group (CPSE:STG) is back in focus after its UK arm revealed a full rebrand of the XQS nicotine pouch range, featuring new packaging, a new logo and detailed flavour profile indicators. See our latest analysis for Scandinavian Tobacco Group. The rebrand lands at a time when momentum in the shares has been relatively positive, with a 30 day share price return of 6.91% and a 90 day share price return of 12.85%. This supports a 5 year total shareholder return of 28.64% at a...

Société Générale has cut its shareholding in ISS A/S (CPSE:ISS) to below 5%, triggering a regulatory disclosure of a change in major shareholder status. The move marks a shift in ISS’s ownership structure that investors may watch for potential implications for governance and market sentiment. ISS, listed as CPSE:ISS, is a global facility services provider. Changes in its major shareholders tend to catch the eye of investors who follow long contract cycles and customer retention trends. The...

ALK-Abelló A/S recently reported full-year 2025 results showing sales of DKK 6,312 million and net income of DKK 1,197 million, confirmed an 11–15% local-currency revenue growth outlook for 2026, announced an annual dividend of DKK 1.60 per share, and disclosed that EVP of R&D Henriette Mersebach will step down in February 2026 while supporting the transition. The combination of stronger earnings, growth guidance under the Allergy+ strategy, and a planned change in R&D leadership highlights...

On 20 February 2026, RWE announced a firm order with Vestas for 92 V236-15.0 MW turbines for the 1,380 MW Vanguard West offshore wind project in the UK, with Vestas supplying, delivering, commissioning, and servicing the turbines under a comprehensive multi-year agreement. This large UK offshore order highlights how Vestas’ V236 platform and service capabilities are being applied at utility scale across a major European project. We’ll now examine how securing this large Vanguard West...

In February 2026, Novo Nordisk reported phase 3 REDEFINE 4 data showing its CagriSema obesity injection delivered less weight loss than Eli Lilly’s Zepbound, while also outlining future high‑dose trials and ongoing REDEFINE and REIMAGINE programs across obesity and type 2 diabetes. At the same time, Novo Nordisk moved to defend its obesity and diabetes franchise with deeper Wegovy price cuts from 2027, an expanded Wegovy 7.2 mg dose in the EU, and new partnerships and pipeline assets,...

Why Demant (CPSE:DEMANT) Is Back in Focus for Investors Demant (CPSE:DEMANT) is drawing fresh attention after gaining market share in the US Veterans Affairs hearing aid channel, while at the same time expanding cost saving layoffs at its Danish operations. See our latest analysis for Demant. The recent gain in US Veterans Affairs market share and the expanded cost-saving program comes after a mixed price pattern, with an 8.07% 7-day share price return, a 30-day share price return of 11.11%,...

DSV (CPSE:DSV) is back in focus after signing a two year Ship Green framework agreement with Hapag Lloyd. The agreement targets 18,000 tonnes of CO₂e emission reductions through sustainable marine fuels in ocean freight. See our latest analysis for DSV. The Ship Green deal comes as DSV’s 90 day share price return of 10.88% contrasts with a softer 30 day share price return of 6.90% and a 12 month total shareholder return of 12.99%. This suggests earlier momentum has cooled recently while...

Vestas Wind Systems (CPSE:VWS) has secured a major turbine order for RWE's 1,380 MW Vanguard West offshore wind project in the United Kingdom. The project adds a large UK offshore scheme to Vestas' order book and relates to a key part of the region's offshore wind pipeline. For you as an investor watching CPSE:VWS, this contract is closely linked to Vestas' core business of supplying wind turbines and related services. Offshore wind has been an area of policy focus in the UK, and government...

FLSmidth (CPSE:FLS) has completed its shift into a pure-play mining technology provider following the divestment of its cement business. The company has appointed Toni Laaksonen as CEO and announced a reshaped Board, including a new proposed Chair and several departures. New executives have been named to lead key mining business lines, signaling an organizational reset around the mining portfolio. FLSmidth now trades as a focused mining technology and services company, with its...

Methanex, Ørsted and Exolum have launched the U.K.’s first commercially ready biomethanol storage and marine bunkering service at the Port of Immingham, providing low‑carbon fuel for shipping and supporting Ørsted’s North Sea offshore wind maintenance vessels. The project shows how existing fuel infrastructure can be re‑tooled for green fuels, offering a practical pathway to cut domestic shipping emissions that currently exceed those from buses, trains and domestic aviation combined in the...

GN Store Nord (CPSE:GN) shares have been reacting to the company’s full year 2025 earnings, in which both sales and net income were lower than the prior year. This has put renewed attention on the stock’s recent performance. See our latest analysis for GN Store Nord. The full year 2025 earnings release appears to have been a key catalyst for the share price, with the stock posting a 1 day share price return of 1.05% and a 7 day share price return of 1.45% after a softer 30 day share price...

Genmab (CPSE:GMAB) has wrapped up FY 2025 with fourth quarter revenue of US$1.1b and basic EPS of US$0.50, rounding out a trailing twelve month EPS of US$15.5 on revenue of US$3.7b. The company has seen quarterly revenue move from US$715 million in Q1 2025 to US$1.1b in Q4, alongside EPS ranging from US$3.06 in Q1 to US$6.51 in Q3 and US$0.50 in Q4. This sets up a results season where investors are likely to focus on how these shifts flow through to margins and the durability of its earnings...

Q1 earnings snapshot and why it matters for shareholders Coloplast (CPSE:COLO B) has just reported first quarter results, with sales of DKK 7,043 million, net income of DKK 1,397 million, and basic earnings per share of DKK 6.2 from continuing operations. See our latest analysis for Coloplast. At a share price of DKK485.0, Coloplast has seen a 30 day share price return of 10.65% decline and a year to date share price return of 9.58% decline, while the 1 year total shareholder return of 36.64%...

Ørsted A/S' ( CPH:ORSTED ) robust earnings report didn't manage to move the market for its stock. We did some digging...

H. Lundbeck (CPSE:HLUN B) is back in focus after reporting positive phase IIb data from the PROCEED trial of bocunebart, a potential migraine preventive therapy targeting patients with prior treatment failures. See our latest analysis for H. Lundbeck. The positive PROCEED data has come just days after Lundbeck reported full year 2025 results and proposed a higher dividend, and the stock has reacted with a 1 day share price return of 2.97% and 7 day share price return of 4.42%. That said, the...